Table 1.
Clinical Trials of combinations of ICIs with myeloid-targeting drugs.
| ICI | Drug | Target | Phase | Clinical trial | References | |
|---|---|---|---|---|---|---|
| α-PD-1 | Nivolumab Pembrolizumab |
Cabiralizumab Cabiralizumab Pexidartinib ARRY-382 AMG 820 |
CSF1R | Phase 1 Phase 2 Phase 1/2 Phase 1/2 Phase 1/2 |
NCT02526017 NCT03336216 NCT02452424 NCT02880371 NCT02713529 |
(139) (140) (141) (142) - |
| α-PD-L1 | Atezolizumab Durvalumab |
Emactuzumab Pexidartinib |
CSF1R | Phase 1 Phase 1 |
NCT02323191 NCT02777710 |
- (143) |
| α-PD-1 | Pembrolizumab | LY3475070 | CD73 | Phase 1 | NCT04148937 | - |
| α-PD-L1 | Atezolizumab Durvalumab |
TJ004309 MEDI9447 |
CD73 | Phase 1 Phase 1 |
NCT03835949 NCT02503774 |
- (144) |
| α-PD-1 | Spartalizumab | PBF-509 | Adenosine-A2A Receptor | Phase 1/2 | NCT02403193 | (145) |
| α-PD-L1 | Atezolizumab Durvalumab |
Ciforadenant (CPI-444) AZD4635 |
Adenosine-A2A Receptor | Phase 1 Phase 1 |
NCT02655822 NCT02740985 |
(146, 147) (148) |
| α-PD-1–α-CTLA-4 | Nivolumab-Ipilimumab | VX15/2503 (Pepinemab) | Semaphorin 4D | Phase 1 Phase 1 Phase 1 Phase 1 |
NCT03690986 NCT03373188 NCT03425461 NCT03769155 |
(149) (149) - (150) |
| α-PD-L1 | Avelumab | VX15/2503 (Pepinemab) | Semaphorin 4D | Phase 1/2 | NCT03268057 | (151) |
| α-PD-1 | Nivolumab Pembrolizumab |
Epacadostat Epacadostat |
IDO-1 | Phase 1 Phase 1/2 Phase 3 Phase 3 Phase 3 Phase 3 Phase 2 Phase 2 Phase 3 |
NCT03707457 NCT02178722 NCT02752074 NCT03260894 NCT03374488 NCT03358472 NCT03322540 NCT03322566 NCT03361865 |
- (152) (153) - (154) (155) (156) (157) (158) |
| α-PD-L1 | Durvalumab | Epacadostat | IDO-1 | Phase 1/2 | NCT02318277 | (159) |
| α-CTLA-4 | Ipilimumab | Epacadostat | IDO-1 | Phase 1/2 | NCT01604889 | (160) |
| α-PD-1 | Nivolumab | IPI-549 | PI3K-γ | Phase 1 Phase 2 |
NCT02637531 NCT03980041 |
(161) |
| α-PD-L1 | Atezolizumab | IPI-549 | PI3K-γ | Phase 2 | NCT03961698 | - |
| α-PD-1 | Nivolumab | APX005M | CD40 | Phase 1/2 Phase 1/2 |
NCT03214250 NCT03123783 |
(162) - |
| α-PD-1 | Pembrolizumab Spartalizumab |
MIW815 MK-1454 GSK3745417 MIW815 |
STING | Phase 2 Phase 1 Phase 1 Phase 1 |
NCT03937141 NCT03010176 NCT03843359 NCT03172936 |
- (163) - (164) |
| α-CTLA-4 | Ipilimumab | MIW815 | STING | Phase 1 | NCT02675439 | - |
| α-PD-1 | Pembrolizumab | ATRA | Retinoic Acid Receptor | Phase 1/2 | NCT03200847 | - |
| α-CTLA-4 | Ipilimumab | ATRA | Retinoic Acid Receptor | Phase 2 | NCT02403778 | (165) |
| α-PD-1 | Nivolumab | Trabectedin | Phase 2 Phase 2 |
NCT03590210 NCT03886311 |
- (166) |
|
| α-PD-L1 | Avelumab Durvalumab |
Trabectedin Trabectedin |
Phase 1/2 Phase 1 |
NCT03074318 NCT03085225 |
- - |
|
| α-PD-1–α-CTLA-4 | Nivolumab-Ipilimumab | Trabectedin | Phase 1/2 | NCT03138161 | (167) | |
| α-PD-1 | Pembrolizumab | Axitinib | VEGF-R | Phase 1 Phase 3 |
NCT02133742 NCT02853331 |
(168) (169) |
| α-PD-L1 | Avelumab | Axitinib | VEGF-R | Phase 3 | NCT02684006 | (170) |
| α-PD-1 | Nivolumab | Bevacizumab | VEGF | Phase 1 Phase 2 Phase 2 |
NCT03382886 NCT03890952 NCT03452579 |
- - (171) |
| α-PD-L1 | Atezolizumab | Bevacizumab | VEGF | Phase 1 Phase 1 Phase 2 Phase 3 Phase 3 |
NCT01633970 NCT02715531 NCT01984242 NCT02366143 NCT02420821 |
(172) (173) (104) (174, 175) (176) |
| α-CTLA-4 | Ipilimumab | Bevacizumab | VEGF | Phase 1 | NCT00790010 | (177–181) |
| α-PD-1 | Pembrolizumab | Trebananib | Angiopoietin-2 | Phase 1 | NCT03239145 | - |